Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Observational 1Interventional 1

Sponsor

Conditions

Breast Neoplasms 3137Neoplasms 2474Carcinoma, Non-Small-Cell Lung 1883Prostatic Neoplasms 1641Colorectal Neoplasms 1432Lung Neoplasms 1308Multiple Myeloma 937Neoplasm Metastasis 926Leukemia, Myeloid, Acute 885Pancreatic Neoplasms 860Ovarian Neoplasms 814Melanoma 791Carcinoma, Hepatocellular 743Stomach Neoplasms 647Recurrence 640Brain Neoplasms 640Squamous Cell Carcinoma of Head and Neck 638Head and Neck Neoplasms 609Glioblastoma 573Uterine Cervical Neoplasms 549Lymphoma 549Triple Negative Breast Neoplasms 514Precursor Cell Lymphoblastic Leukemia-Lymphoma 511Carcinoma, Renal Cell 504Endometrial Neoplasms 467Hematologic Neoplasms 464Urinary Bladder Neoplasms 462Colonic Neoplasms 447Lymphoma, Non-Hodgkin 437Sarcoma 436

Interventions

Miransertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Proteus Syndrome × 1 year × Clear all
NCT04316546 2026-06-04

MK-7075 (Miransertib) in Proteus Syndrome

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
38 enrolled

Proteus Syndrome

NCT00001403 2026-05-22

Study of Proteus Syndrome and Related Congenital Disorders

National Institutes of Health Clinical Center (CC)

Recruiting
1,500 enrolled

Abnormalities, Multiple, Growth Disorders, Proteus Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡